CK2-dependent phosphorylation of Progesterone Receptors mediates proliferative si
CK2-dependent phosphorylation of Progesterone Receptors mediates proliferative si
批准号:
9040904
负责人:
Christy Hagan
金额:
$24.9万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-09-23 至 2018-03-31
关键词:
BindingBinding ProteinsBinding SitesBiologyBreastBreast Cancer CellBreast Cancer PreventionBreast CarcinomaCancerousCarcinomaCell MaintenanceCell ProliferationCellsDUSP6 proteinDataDevelopmentDockingEstrogen ReceptorsEventGene Expression RegulationGene TargetingGenesGenetic TranscriptionGenomicsGoalsHyperplasiaKnockout MiceLigandsMaintenanceMammary NeoplasmsMammary glandMediatingMusN-terminalOvarian Steroid HormonePhosphorylationProgesteroneProgesterone ReceptorsProtein IsoformsProteinsRecruitment ActivityRegulationResearch ProposalsSerineSignal TransductionStat5 proteinStem cellsSteroid ReceptorsTissuesUterusbasebreast lesiongenetic signaturegenome-widehormone therapymalignant breast neoplasmmouse developmentnovelpreventprogesterone receptor Aprogesterone receptor Bpromoterreceptortumor progressionwhole genome
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
Progesterone is an ovarian steroid hormone essential for breast development. The progesterone receptor (PR)
exists primarily in two co-expressed isoforms, PR-A and PR-B. Studies from knockout-mice have shown that
PR-B is required for proliferative signaling during mammary gland alveologenesis. In contrast, PR-A is required
for uterine development, where progesterone inhibits proliferation. Very little is understood regarding regulation
of PR tissue- and isoform-specific transcription. How are isoform-specific mitogenic (PR-B in the breast) and
inhibitory/differentiative (PR-A in the uterus) effects achieved? PR-A and PR-B are most often co-expressed in
the same tissues, and cells that express only a single PR isoform are rare, except in breast cancer where the
normal 1:1 ratio is frequently altered. Selective PR isoform inhibition (blocking pro-proliferative effects of PR-B
while preserving the protective or anti-proliferative effects of PR-A) would represent significant progress in
breast cancer prevention and/or treatment. PR is highly post-translationally modified. Phosphorylation,
primarily on PR-B N-terminal serine residues, significantly alters receptor stability, localization, transcriptional
activity and promoter selectivity. Our preliminary data suggest that the basis for PR-B-specific proliferative
actions in breast cancer cells involves ck2-dependent selective phosphorylation of PR-B Ser81 via a unique
protein interaction domain, the common docking (CD) domain, found exclusively in PR-B but not PR-A.
Phosphorylation of PR-B Ser81 regulates a highly specific subset of proliferative and pro-survival genes,
including selected PR-regulated genes known to modulate the mammary stem cell compartment, such as
Wnt1 and STAT5A. Additionally, our data suggest that STAT5A may serve as a “pioneer factor”, an early
genomic binding partner that recruits/directs phospho-Ser81-PR-B-specific gene regulation. The goal of this
research proposal is to determine how proteins that interact with PR-B via the CD domain regulate direct
phosphorylation of PR-B on Ser81, thereby dictating PR-B isoform-specific transcriptional events at genes
important for breast cancer cell proliferation, pro-survival, and expansion of the stem cell compartment.
Hypothesis: PR and STAT5 co-regulate a specific subset of phospho-PR-B target genes (through CD domain-
dependent recruitment of MKP3 and ck2, followed by ck2-mediated phosphorylation of PR-B Ser81) that
regulate breast cancer cell proliferation and pro-survival, in part via modulation of the mammary stem cell
compartment; selected genes are regulated by phospho-PR-B in the absence of ligand. ck2-dependent
activation of PR-B may accelerate mammary tumor development and/or drive early breast cancer progression.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting the Progesterone Receptor as a Novel Means to Increase Efficacy of Immune Checkpoint Inhibitors in Hormone Receptor Positive Breast Cancer
-
批准号:10512899
-
项目类别:
-
资助金额:$25.56万
-
财政年份:2022
-
负责人:Christy Hagan
-
依托单位:
CK2-dependent phosphorylation of Progesterone Receptors mediates proliferative si
-
批准号:8531690
-
项目类别:
-
资助金额:$9.75万
-
财政年份:2012
-
负责人:Christy Hagan
-
依托单位:
CK2-dependent phosphorylation of Progesterone Receptors mediates proliferative si
-
批准号:8278299
-
项目类别:
-
资助金额:$9.21万
-
财政年份:2012
-
负责人:Christy Hagan
-
依托单位:
海外基金